Suppression of Established T Cell Immunity and Disease by Immunotherapy with Synthetically Glycosylated Antigen

The purpose of this study was to conduct an in-depth analysis of the molecular characteristics of both CD4 and CD8 T cells upon encounter of self-associated antigen presented by hepatic APCs, induce therapeutic tolerance in transgenic and endogenous repertoires of T cells, and discover the mechanisms that mediate pGal-induced tolerance. Overall design: Prophylactic: Ovalbumin-specific CD4 and CD8 T cell mRNA profiles of WT mice 4 days post antigen treatment. Day 0 mice received adoptive transfer of OTI and OTII cells. At 1 day post transfer mice received either 5ug pGal-OVA, 5ug plain OVA, or saline. At Day 5, secondary lymphoid organs were collected and pooled. Each replicate was generated from fluorescent activated cell sorted OTI and OTII cells pooled from 3 mice. Therapeutic: Mice received adoptive transfer of OTI and OTII cells on Day 0, followed by s.c. immunization with CFA+OVA the next day. One month later mice received either 5ug pGal-OVA, 5ug plain OVA, or saline. 4 days after antigen treatment secondary lymphoid organs were collected and pooled. Each sample consists of one mouse.